Abstract

FORMULATION AND EVALUATION OF LAMIVUDINE SUSTAINED RELEASE MATRIX TABLETS USING JACKFRUIT SEED EXTRACT AS RELEASE RETARDANT

Dr. M. Sunitha Reddy* and Vasam Tweja

ABSTRACT

Lamivudine is used for treating the human immunodeficiency virus infection & chronic hepatitis-B. It is nucleoside reverse transcriptase inhibitor. Lamivudine is a anti-retriviral drug. It has half life of 5-7 hours. Therefore the main objective of the present work is to develop sustained release matrix tablets of Lamivudine using naturalexipient, jackfruit seed starch. Lamivudine showed maximum absorbance at a wavelength of 279 nm in 0.1N HCL. Drug excipient compatibility studies by FTIR, Studies gave conformation that there was no interaction between drug and selected formulations. Various formulations were developed by using various concentrations of jackfruit seed starch in the range of 50-300 mg using direct compression method. The physico chemical characteristics of lamivudine, jackfruit seed starch were determined and pre-compressional and post-compressional parameters of the designed formulations were evaluated. From all the developed formulations F9 has prolonged the drug release up to 12 hours and is selected as best formulation. All the formulations had sustained release of the drug upto 10 hours and optimized formulations F9 showed sustained released time for more than 12 hours. The optimized formulation F9 was found to be stable even after the stability studies conducted for a period of one month. Thus the formulation satisfied physico-chemical parameters and in vitro drug release profile requirements for sustained release drug delivery systems.

Keywords: jackfruit seed starch, Lamivudine, direct compression method, sustained released drug delivery systems.